ETHACRYNATE SODIUM FOR INJECTION USP POWDER FOR SOLUTION

Land: Canada

Språk: engelsk

Kilde: Health Canada

Aktiv ingrediens:

ETHACRYNIC ACID (ETHACRYNATE SODIUM)

Tilgjengelig fra:

STERIMAX INC

ATC-kode:

C03CC01

INN (International Name):

ETACRYNIC ACID

Dosering :

50MG

Legemiddelform:

POWDER FOR SOLUTION

Sammensetning:

ETHACRYNIC ACID (ETHACRYNATE SODIUM) 50MG

Administreringsrute:

INTRAVENOUS

Enheter i pakken:

1VIAL

Resept typen:

Prescription

Terapeutisk område:

LOOP DIURETICS

Produkt oppsummering:

Active ingredient group (AIG) number: 0101703001; AHFS:

Autorisasjon status:

APPROVED

Autorisasjon dato:

2017-11-02

Preparatomtale

PRODUCT MONOGRAPH
Intravenous
Pr
ETHACRYNATE SODIUM FOR INJECTION USP
Lyophilized powder for injection, 50 mg equivalent to ethacrynic acid
PHARMACOLOGICAL CLASSIFICATION
Saluretic-Diuretic Agent
SteriMax Inc.
Date of Preparation:
2770 Portland Drive
November 1, 2017
Oakville, ON L6H 6R4
Control No. 204211
PRODUCT MONOGRAPH
Intravenous
Pr
ETHACRYNATE SODIUM FOR INJECTION USP
Lyophilized powder for injection, 50 mg equivalent to ethacrynic acid
PHARMACOLOGICAL CLASSIFICATION
Saluretic-Diuretic Agent
ACTION AND CLINICAL PHARMACOLOGY
Ethacrynic acid is a saluretic-diuretic agent with marked potency and
rapid onset of action. It is
chemically unrelated to other diuretics. Patients with congestive
heart failure (including acute
pulmonary edema), renal edema, hepatic cirrhosis with ascites, and
other conditions involving
fluid retention have responded well to ethacrynic acid.
Ethacrynic acid has the following major characteristics:
(1) WATER AND ELECTROLYTE EXCRETION may be increased several times
over that observed with
thiazide diuretics. The urinary output is usually dose-dependent and
related to the magnitude of
fluid accumulation.
(2) ELECTROLYTE EXCRETION PATTERN DIFFERS FROM THAT OF THIAZIDES.
Initially, sodium and chloride
excretion is usually substantial, and chloride loss exceeds that of
sodium. With prolonged
therapy, chloride excretion declines, and potassium and hydrogen ion
excretion may increase.
In patients with increased diuresis excessive amounts of potassium may
be excreted.
Ethacrynic acid is effective whether or not there is clinical acidosis
or alkalosis.
(3) RAPID ONSET OF ACTION usually is observed within 5 minutes after
an intravenous injection.
(4) SULFHYDRYL BINDING PROPENSITY differs in certain respects from
that of the organomercurials.
Its mode of action is not by carbonic anhydrase inhibition.
(5) MULTIPLE SITES OF ACTION. Ethacrynic acid acts on the proximal and
distal portions of the
tubule, and also on the ascending limb of the loop of Henle.
INDICATIONS AND CLINICAL USE
Ethacrynate So